Summary
Carboxyl labelled l-dopa was administered orally and intravenously to Parkinsonian patients and control subjects. Total radioactivity was measured in the expired air, urine and plasma. The activity in plasma was also measured before and after removal of carbon dioxide-dicarbonate. After intravenous administration about four times more radioactivity was recovered in the urine than after oral administration with a roughly corresponding decrease in the recovery from expired air, whereas a considerably smaller proportion of the total radioactivity in plasma was derived from carbon dioxide-bicarbonate. It is concluded that the major fraction of the orally administered l-dopa undergoes decarboxylation in the digestive tract before reaching the general circulation. No difference was observed between the Parkinsonian and the non-Parkinsonian group.
References
Bartholini, G., Pletscher, A., Kuruma, I.: Metabolism of l-dopa after inhibition of extracerebral decarboxylation and metabolic fate of l-3-O-methyldopa. In: J. de Ajuriaguerra and G. Gauthier (eds.): Monoamines, noyaux gris centraux et syndrome de Parkinson, pp. 85–98. Genéve 1971.
Rivera-Calimlim, L., Morgan, J. P., Dujovne, C. A., Bianchine, J. R., Lasagna, L.: l-3,4-dihydroxyphenylalanine metabolism by the gut in vitro. Biochem. Pharmacol. 20, 3051–3057 (1971).
Tissot, R., Bartholini, G., Pletscher, A.: Drug-induced changes of extracerebral dopa metabolism in man. Arch. Neurol. (Chic.) 20, 187–190 (1969).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bergmark, J., Carlsson, A., Granerus, AK. et al. Decarboxylation of orally administered l-dopa in the human digestive tract. Naunyn-Schmiedeberg's Arch. Pharmacol. 272, 437–440 (1972). https://doi.org/10.1007/BF00501249
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00501249